highly variable drugs-Cmax [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-11-19 21:58 (1276 d 16:48 ago) – Posting: # 22070
Views: 2,057

Hi Osama,

❝ Although the GCC GL is adopted from the EMA GL, but the upper cap of scaling is about only 39% and not 50%!!!!


library(PowerTOST)
noquote(sprintf("%.2f%%", 100*U2CVwR(U = 1/0.75)))
[1] 39.25%

:-D

I wouldn’t call that scaling. The GL calls for fixed limits of 75.00–133.33% (based on a “clinically not relevant Δ” of 25%) for any CVwR >30% (there is no upper cap and the widened limits are fixed).
That’s the approach mentioned in the EMA’s Q&A-document of July 2006:

[image]

BTW, with fixed limits there are no issues with inflation of the type I error* like in all reference-scaling methods (EMA, Health Canada, FDA). When discussing the EMA’s draft, sponsors complained that ABEL is more restrictive at CVwR 30–39.25% than the “old” approach…

❝ At the moment, I think you could have a good chance under the conditions that your BE study is demonstrated in a replicate design and that the high within-subject variability for Cmax not caused by outliers.


That’s interesting!



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
33 visitors (0 registered, 33 guests [including 6 identified bots]).
Forum time: 15:47 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5